Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.

Verma S, Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Rönnbäck C, Abildstrøm SZ, Liisberg K, Wolf D, von Lewinski D and 4 more

Show all authors

Lelonek M, Melenovsky V, Senni M, Kosiborod MN

Journal of the American College of Cardiology30 Aug 2024Cited by 62 (Europe PMC)

PMID39217564DOI10.1016/j.jacc.2024.08.028PepBankPUB-39217564

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity-related HFpEF, semaglutide versus placebo reduced heart failure-related symptoms and physical limitations, consistently across baseline CRP categories.
In plain wordsIn adults with obesity-related heart failure, semaglutide eased heart failure symptoms more than placebo, whatever the starting level of inflammation.
Peptide
Semaglutide
Outcome
IncreaseKCCQ-CSS (heart failure symptoms and physical limitations) across baseline CRP categories
Study
n = 1,145
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide vs placebo led to reductions in HF-related symptoms and physical limitations as well as body weight, and to improvements in 6MWD and the hierarchical composite endpoint that were consistent across baseline CRP categories (all P interaction nonsignificant).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a secondary analysis of pooled data from 2 international, double-blind, placebo-controlled, randomized trials (STEP-HFpEF and STEP-HFpEF DM).
Report a problemFND-3921756401
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity-related HFpEF, semaglutide versus placebo reduced body weight, consistently across baseline CRP categories.
In plain wordsIn adults with obesity-related heart failure, semaglutide lowered body weight more than placebo, whatever the starting level of inflammation.
Peptide
Semaglutide
Outcome
DecreaseBody weight across baseline CRP categories
Study
n = 1,145
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide vs placebo led to reductions in HF-related symptoms and physical limitations as well as body weight, and to improvements in 6MWD and the hierarchical composite endpoint that were consistent across baseline CRP categories (all P interaction nonsignificant).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a secondary analysis of pooled data from 2 international, double-blind, placebo-controlled, randomized trials (STEP-HFpEF and STEP-HFpEF DM).
Report a problemFND-3921756402
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity-related HFpEF, semaglutide versus placebo improved 6-minute walk distance, consistently across baseline CRP categories.
In plain wordsIn adults with obesity-related heart failure, semaglutide improved walking distance more than placebo, whatever the starting level of inflammation.
Peptide
Semaglutide
Outcome
Increase6-minute walk distance across baseline CRP categories
Study
n = 1,145
Comparator
Placebo
Outcome group
Exercise and physical function · Cardiovascular
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide vs placebo led to reductions in HF-related symptoms and physical limitations as well as body weight, and to improvements in 6MWD and the hierarchical composite endpoint that were consistent across baseline CRP categories (all P interaction nonsignificant).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a secondary analysis of pooled data from 2 international, double-blind, placebo-controlled, randomized trials (STEP-HFpEF and STEP-HFpEF DM).
Report a problemFND-3921756403
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity-related HFpEF, semaglutide versus placebo improved the hierarchical composite endpoint, consistently across baseline CRP categories.
In plain wordsIn adults with obesity-related heart failure, semaglutide improved a combined heart score more than placebo, whatever the starting level of inflammation.
Peptide
Semaglutide
Outcome
IncreaseHierarchical composite endpoint across baseline CRP categories
Study
n = 1,145
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide vs placebo led to reductions in HF-related symptoms and physical limitations as well as body weight, and to improvements in 6MWD and the hierarchical composite endpoint that were consistent across baseline CRP categories (all P interaction nonsignificant).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a secondary analysis of pooled data from 2 international, double-blind, placebo-controlled, randomized trials (STEP-HFpEF and STEP-HFpEF DM).
Report a problemFND-3921756404
05HumanRandomized controlled trialEfficacy outcome
The effects of semaglutide versus placebo on key outcomes did not differ significantly across baseline CRP categories (all interaction P values nonsignificant).
In plain wordsThe benefits of semaglutide over placebo did not differ clearly between people with lower and higher starting inflammation.
Peptide
Semaglutide
Outcome
No significant changeInteraction of baseline CRP with treatment effect on key outcomes
Study
n = 1,145
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide vs placebo led to reductions in HF-related symptoms and physical limitations as well as body weight, and to improvements in 6MWD and the hierarchical composite endpoint that were consistent across baseline CRP categories (all P interaction nonsignificant).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a secondary analysis of pooled data from 2 international, double-blind, placebo-controlled, randomized trials (STEP-HFpEF and STEP-HFpEF DM).
Report a problemFND-3921756405
06HumanRandomized controlled trialEfficacy outcome
Semaglutide reduced CRP to a greater extent than placebo regardless of baseline CRP levels.
In plain wordsSemaglutide lowered the inflammation marker CRP more than placebo, whatever the starting level.
Peptide
Semaglutide
Outcome
DecreaseCRP reduction
Study
n = 1,145
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide also reduced CRP to a greater extent than placebo regardless of baseline CRP levels (P interaction = 0.32).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a secondary analysis of pooled data from 2 international, double-blind, placebo-controlled, randomized trials (STEP-HFpEF and STEP-HFpEF DM).
Report a problemFND-3921756406
07HumanRandomized controlled trialMechanism
Change in CRP from baseline to 52 weeks was similar regardless of the magnitude of weight loss.
In plain wordsThe fall in the inflammation marker CRP was similar whether people lost less or more weight.
Peptide
Semaglutide
Outcome
No significant changeRelationship between CRP change and weight loss
Study
n = 1,145
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
Change in CRP from baseline to 52 weeks was similar regardless of the magnitude of weight loss (P interaction = 0.91).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a secondary analysis of pooled data from 2 international, double-blind, placebo-controlled, randomized trials (STEP-HFpEF and STEP-HFpEF DM).
Report a problemFND-3921756407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT04916470

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

Novo Nordisk A/Sn = 61715 Jun 2021 to 11 Oct 2023

Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 26 Nov 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.